Cancer drug receives NHS approval

One lung cancer drug receives NHS England approval, while another is rejected

Article courtesy of Cancer Research UK.

A targeted drug has been accepted for routine use on the NHS in England for some adults with untreated, advanced lung cancer. But another precision drug, for the same group of patients, has been rejected due to questions over its cost-effectiveness. 

Read the full article here: 

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.